Nicolas Hubacz: How Psychoactive Drugs Alter Spider Web Construction
Nicolas Hubacz, Research and Clinical Products Business Development Manager at Magstim, shared a post on LinkedIn:
“How Psychoactive Drugs Alter Spider Web Construction
In 1995, scientists explored how different drugs influence spider web construction to understand their impact on behavior and motor skills. This research was initiated due to a zoologist’s request to alter the time garden spiders build their webs. The team administered various psychoactive substances, such as amphetamine, mescaline, strychnine, LSD, and caffeine, observing changes in web size and shape rather than timing.
Low caffeine doses led to smaller webs with uneven radii, while higher doses resulted in even smaller, irregular designs. Each drug induced different effects: sleeping pills caused drowsiness and incomplete webs, Benzedrine created zigzag patterns, marijuana resulted in missing inner sections, and scopolamine disrupted directional sense.
The study highlighted how drugs affect spider behavior, offering insights into the broader impacts of psychoactive substances across species.”
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 11:16Ocima Richard Draza: Postpartum Hemorrhage – A Practical Step-by-Step Management Guide
-
Jun 1, 2026, 10:57Kyungjun Lim: How Will Future Mars Colonies Manage Their Supply Chains?
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership